Evidence map›Paper›PMID 38443601›Full record

ArticleActa neuropathologica2024

RNA aptamer reveals nuclear TDP-43 pathology is an early aggregation event that coincides with STMN-2 cryptic splicing and precedes clinical manifestation in ALS.

Holly Spence, Fergal M Waldron, Rebecca S Saleeb, Anna-Leigh Brown, Olivia M Rifai, Martina Gilodi, Fiona Read, Kristine Roberts, Gillian Milne, Debbie Wilkinson and 8 more

Open access · hybridAbstract read
In one paragraph

Article in Acta neuropathologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
17.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Review
  3. TDP-43: [GU]-ardian of the transcriptome.Molecular neurodegeneration · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Neuronal TDP-43 regulates myelin formation via neurexin 1 mRNA stabilization.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  8. Aberrant Splicing Signatures Underpin Oligodendrocyte Damage in ALS and Neuron Loss in FTD.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 8 institutions in 3 countries.

Holly Spence *Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK.
Fergal M Waldron *Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK.
Rebecca S SaleebEaStCHEM School of Chemistry, University of Edinburgh, Edinburgh, UK.
Anna-Leigh BrownDepartment of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK.
Olivia M RifaiCentre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, UK.
Martina GilodiRNA System Biology Lab, Instituto Italiano di Tecnologia, Genoa, Italy.
Fiona ReadInstitute of Medical Sciences, University of Aberdeen, Aberdeen, UK.
Kristine RobertsDepartment of Pathology, NHS Grampian Tissue Biorepository, Aberdeen, UK.
Gillian MilneInstitute of Medical Sciences, University of Aberdeen, Aberdeen, UK.
Debbie WilkinsonInstitute of Medical Sciences, University of Aberdeen, Aberdeen, UK.
Judi O'ShaughnessyEaStCHEM School of Chemistry, University of Edinburgh, Edinburgh, UK.
Annalisa PastoreThe Maurice Wohl Institute, King's College London, London, UK.
Pietro FrattaDepartment of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK.
Neil ShneiderDepartment of Neurology, Center for Motor Neuron Biology and Disease, Columbia University, New York, NY, USA.
Gian Gaetano TartagliaRNA System Biology Lab, Instituto Italiano di Tecnologia, Genoa, Italy.
Elsa ZaccoRNA System Biology Lab, Instituto Italiano di Tecnologia, Genoa, Italy.
Mathew H Horrocks *EaStCHEM School of Chemistry, University of Edinburgh, Edinburgh, UK. mathew.horrocks@ed.ac.uk.
Jenna M Gregory *Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK. jenna.gregory@abdn.ac.uk.ORCID 0000-0003-3337-4079
University of Aberdeen · GBItalian Institute of Technology · ITMRC Centre for Regenerative Medicine · GBNational Hospital for Neurology and Neurosurgery · GBColumbia University · USKing's College London · GBNHS Grampian · GBUniversity of Edinburgh · GB

Funding

The Physical Biology of Neurodegeneration in Sporadic Amyotrophic Lateral Sclerosis/Frontotemporal DementiaR01NS127186 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HOLT, LIAM J, PHATNANI, HEMALI · 2021 to 2025
$8.2M
Medical Research Council MR/S006508/1NIH HHS R01NS127186NINDS NIH HHS R01 NS127186
6 · The paper itself

Abstract

TDP-43 is an aggregation-prone protein which accumulates in the hallmark pathological inclusions of amyotrophic lateral sclerosis (ALS). However, the analysis of deeply phenotyped human post-mortem samples has shown that TDP-43 aggregation, revealed by standard antibody methods, correlates poorly with symptom manifestation. Recent identification of cryptic-splicing events, such as the detection of Stathmin-2 (STMN-2) cryptic exons, are providing evidence implicating TDP-43 loss-of-function as a potential driving pathomechanism but the temporal nature of TDP-43 loss and its relation to the disease process and clinical phenotype is not known. To address these outstanding questions, we used a novel RNA aptamer, TDP-43

Indexed as

Amyotrophic Lateral SclerosisAptamers, NucleotideAntibodiesDNA-Binding ProteinsHumansRNA SplicingAntibodiesAptamers, NucleotideDNA-Binding ProteinsAmyotrophic lateral sclerosisCognitionCryptic splicingLoss-of-functionNeuropathologyRNA aptamerStathmin-2TDP-43

Identifiers

PMID38443601
PMCPMC10914926
OpenAlexW4392448526

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.